US: Senate Committee Investigates Prices of Novo’s Ozempic and Wegovy

A US Senate committee said Wednesday it has launched an investigation into the prices of Novo Nordisk’s Ozempic and Wegovy drugs in the United States.

Sen. Bernie Sanders, chairman of the Senate Health, Education, Labor and Pensions Committee, sent a letter to Novo’s CEO asking for more information about the US prices of the two drugs, which are higher than prices in other countries.

The committee also asked Novo whether it intends to significantly reduce both the list price and the net price of the two drugs, as well as why the company charges a higher price for the weight loss drug Wegovy than Ozempic, which contains the same compound .

“Novo Nordisk remains committed to working with policymakers to advance solutions that support access and affordability for all patients, and we reiterated that commitment in our conversation with President Sanders,” the company said in a statement to Reuters.

Ozempic, approved for patients with diabetes, and Wegovy belong to a class of drugs that reduce the desire to eat and cause the stomach to empty more slowly.

Moneyreview.gr

Read also:

Ozempic: How cybercriminals trick those who want to lose weight

Novo Nordisk foundation: Gradual increase in non-Danish grants

And the winner of this year’s Oscars….is Ozempic

Novo Nordisk’s market cap has overtaken Tesla’s

Follow Money Review on Google News